Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
CAD106
National Institutes of Health
Create Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease
C. Lopez Lopez
,
Pierre N Tariot
,
+13 authors
E. Reiman
Alzheimer's & dementia
2019
Corpus ID: 189930724
Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta (Aβ) species and tau pathology, begins decades…
Expand
Review
2017
Review
2017
Amyloid beta: structure, biology and structure-based therapeutic development
Guo-fang Chen
,
Ting-Hai Xu
,
+4 authors
H. Xu
Acta Pharmacologica Sinica
2017
Corpus ID: 13656373
Amyloid beta peptide (Aβ) is produced through the proteolytic processing of a transmembrane protein, amyloid precursor protein…
Expand
2017
2017
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
R. Vandenberghe
,
Marie‐Emmanuelle Riviere
,
+8 authors
A. Graf
Alzheimer's & dementia
2017
Corpus ID: 20560457
This randomized, double‐blind, placebo‐controlled, 90‐week study assessed safety, tolerability, and immunogenicity of CAD106 with…
Expand
Highly Cited
2015
Highly Cited
2015
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
M. Farlow
,
N. Andreasen
,
+6 authors
A. Graf
Alzheimer's Research & Therapy
2015
Corpus ID: 9461487
IntroductionCAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses…
Expand
Review
2014
Review
2014
Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
F. Panza
,
V. Solfrizzi
,
B. Imbimbo
,
R. Tortelli
,
A. Santamato
,
G. Logroscino
Expert review of clinical immunology
2014
Corpus ID: 38913139
Both active and passive anti-β-amyloid (Aβ) immunotherapies for the treatment of Alzheimer's disease (AD) have demonstrated…
Expand
Review
2014
Review
2014
Alzheimer disease immunotherapeutics: Then and now
Harashish Jindal
,
Bhumika Bhatt
,
Shashikantha Sk
,
Jagbir Singh Malik
Human vaccines & immunotherapeutics
2014
Corpus ID: 21172119
Dementia is a public health priority and one of the major contributors to morbidity and global non-communicable disease burden…
Expand
Highly Cited
2012
Highly Cited
2012
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
B. Winblad
,
N. Andreasen
,
L. Minthon
,
A. Floesser
,
A. Graf
The Lancet Neurology
2012
Corpus ID: 42166910
BACKGROUND Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer's…
Expand
2012
2012
Alzheimer disease: Amyloid-β immunotherapy CAD106 passes first safety test in patients with Alzheimer disease
Katie Kingwell
Nature Reviews Neurology
2012
Corpus ID: 205515313
Alzheimer disease: Amyloid-β immunotherapy CAD106 passes first safety test in patients with Alzheimer disease
2012
2012
Active immunotherapy for Alzheimer's disease
T. Wisniewski
The Lancet Neurology
2012
Corpus ID: 40660176
Alzheimer’s disease is the most common cause of dementia globally, affecting about 36 million people at present and with about…
Expand
Highly Cited
2011
Highly Cited
2011
The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
Christoph Wiessner
,
K. Wiederhold
,
+11 authors
M. Staufenbiel
The Journal of Neuroscience
2011
Corpus ID: 5920949
Immunization against amyloid-β (Aβ) can reduce amyloid accumulation in vivo and is considered a potential therapeutic approach…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE